

Biomarker testing:


How results guide lung cancer treatment




The majority of people with non-small cell lung cancer (NSCLC) have characteristics, called biomarkers, that can be identified through testing. Not all lung cancers have biomarkers, but knowing whether they are present helps doctors better understand the subtype and inform treatment decisions.^{1,2}

Biomarker testing is relevant for all patients with NSCLC, regardless of the stage of disease.³


Resectable NSCLC: Early-stage disease, when the tumour can be removed through surgery.⁴



Unresectable NSCLC: The cancer has progressed to an advanced stage and the tumour can no longer be removed by surgery.⁴




It is recommended to talk to your doctor about testing before starting therapy - at diagnosis, recurrence or progression.⁵




Test results can confirm if certain biomarkers are present or not, which can help guide treatment.^{3,4}


These treatments may be given alone or alongside surgery:



Chemotherapy



Targeted therapy



Cancer immunotherapy

Ask your doctor about testing.

Improved understanding of biomarkers has changed the way that certain types of lung cancer can be treated. Biomarker testing and knowing your lung cancer's subtype can help you and your healthcare team make fully informed treatment decisions.

References

1. Pakkala S. and Ramalingam S.S. Personalized therapy for lung cancer: striking a moving target. JCI insight. 2018;3(15)
2. National Cancer Institute. Biomarker Testing for Cancer Treatment. Available from: <https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment>. Accessed July 2023
3. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed July 2023.
4. Cancer.net. Information about Non-Small Cell Lung Cancer. Available from: <https://www.cancer.net/cancer-types/lung-cancer/view-all>. Accessed July 2023
5. Kerr M., et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. 2021;154:161-175